Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments

Table 1

Enhanced ratio (%) of tumor and muscle from in vivo MR imaging.

	Pretargeting ()	Nonpretargeting ()	USPIO ()	value
Tumor	31.8 ± 0.5	5.6 ± 0.5	6.1 ± 0.7	0.000
Muscle	4.6 ± 0.4	4.7 ± 0.3	4.9 ± 0.6	0.572